OncoMatch/Clinical Trials/NCT07148128
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Is NCT07148128 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies WEF-001 for advanced or metastatic kras-mutant tumor in pancreatic adenocarcinoma.
Treatment: WEF-001 — This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Colorectal Cancer
Small Cell Lung Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS mutation
Disease stage
Metastatic disease required
Advanced KRAS-mutant solid tumor
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care therapy
Progressive disease following at least one line of standard of care therapy
Lab requirements
Liver function
Liver dysfunction [excluded]
Cardiac function
Active cardiovascular disease [excluded]
Liver dysfunction; Active cardiovascular disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NEXT Oncology Dallas · Dallas, Texas
- Next Oncology, San Antonio · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify